New data show that LEO Pharma's Kyntheum (brodalumab) sustains PASI 100 scores longer than ustekinumab for people with moderate-to-severe plaque psoriasis
BALLERUP, Denmark--(BUSINESS WIRE)--Apr 25, 2019--LEO Pharma A/S, a global leader in medical dermatology, today announced that new data presented this week at the 6th Congress of t…
